Molecular bacteriotherapy to control skin enzymatic activity
AssigneeThe Regents of the University of California
InventorsRichard L. Gallo, Michael Williams
Life of this patent
Estimating the term…
Abstract
The disclosure relates to composition and methods to treat dermatological diseases and disorders and to composition that modulate skin barrier permeability.
Claims21
1-37. (canceled)
A method of treating a dermatological disorder comprising administering an effective amount of a composition comprising a polypeptide comprising a sequence that is at least 98% identical to SEQ ID NO:4.
A method of treating atopic dermatitis comprising administering an effective amount of at least one coagulase negative Staphylococcus sp. (CoNS) or an effective amount of a fermentation extract of CoNS, wherein the CoNS is capable of producing a polypeptide comprising the sequence of SEQ ID NO:
- 4.
A method of treating a skin disease or disorder, comprising:
- measuring a protease activity of a culture from skin of a subject or of skin from the subject;
- comparing the protease activity to a normal control;
- and
- administering an effective amount of a composition comprising a polypeptide comprising a sequence that is at least 98% identical to SEQ ID NO:
- 4.
Dependencies are inferred from the claim text.